z-logo
open-access-imgOpen Access
Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?
Author(s) -
Xavier Pivot,
David G. Cox,
Joseph Gligorov
Publication year - 2017
Publication title -
chinese clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.733
H-Index - 22
eISSN - 2304-3873
pISSN - 2304-3865
DOI - 10.21037/cco.2017.10.07
Subject(s) - pertuzumab , medicine , adjuvant , breast cancer , oncology , trastuzumab , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom